Search results
ImmunoReagents is a US manufacturer of antibodies and reagents for research and diagnostics. Download its free 96-Well ELISA Plate Template to simplify data entry and printing.
- ELISA & Western Blot Reagents
ELISA & Western Blot Reagents - 96-Well ELISA Plate Template...
- Primary Antibodies
Primary Antibodies - 96-Well ELISA Plate Template...
- Tag Antibodies & TR-Fret Reagents
Tag Antibodies & TR-Fret Reagents - 96-Well ELISA Plate...
- Normal Serums
Normal Serums - 96-Well ELISA Plate Template (Printable) -...
- Immunoglobulins
Immunoglobulins - 96-Well ELISA Plate Template (Printable) -...
- Secondary Antibodies
Secondary Antibodies - 96-Well ELISA Plate Template...
- ELISA & Western Blot Reagents
Learn how to conduct an ELISA assay using a 96-well plate with antigen, antibody, and labeled secondary antibody. Find materials, steps, troubleshooting tips, and references from ImmunoReagents, a US manufacturer of quality antibodies and reagents.
ImmunoReagents offers a variety of reagents optimized for ELISA, IHC, Western Blots and other immunoassay formats. HRP, Biotin, Streptavidin and Alkaline Phosphatase conjugates have been fully optimized for peak assay performance.
The enzyme linked immunosorbent assay (ELISA) is a powerful method for detecting and quantifying a specific protein in a complex mixture. Originally described by Engvall and Perlmann (1971), the method enables analysis of protein samples immobilized in microplate wells using specific antibodies.
2 maj 2018 · Enzyme Linked Immunosorbent Assay. Also known simply as ELISA, it is a testing platform that uses antibodies to detect target molecules through specific binding and emission of light from a substrate. The analysis material containing an unknown amount of antigen is immobilized in a tube or microtiter plate.
Careful selection of ELISA components such as antibody, buffer, and substrate is needed for best performance. Plate types and antibody labeling are key considerations.
The first immunoassay used a bridging ELISA capable of detecting 10 ng/mL pos. control anti-panitumumab Ab. The ELISA incorporated an acid dissocn. step to reduce drug interference and tolerated the presence of ∼100-fold molar excess of drug. During eight clin. trials, the ELISA detected developing Ab responses in 2 of 612 (0.3%) subjects.
